Maximising the use of β-blockers for hypertension control.

In recent decades, the global prevalence of hypertension (HTN) – a significant risk factor for cardiovascular disease (CVD)– has been rising owing to multiple factors, such as economic growth and an ageing population. HTN is associated with various health complications, including myocardial infarction, stroke and renal failure. Additionally, it is considered a primary cause of cardiovascular (CV) mortality. According to data from the 2019 National Health and Morbidity Survey, about 30% of Malaysian adults are affected by HTN, and this prevalence increases with age. The management of HTN encompasses both non-pharmacological strategies, such as lifestyle modification, and pharmacological interventions that include a range of antihypertensive medications.